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Plasma adiponectin and resistin levels in women with
polycystic ovary syndrome: relation to body mass index and
insulin resistance
Emre DİKMEN1, İlhan TARKUN2, Funda ÖZTÜRK2, Berrin ARSLAN2, Zeynep CANTÜRK2

Aim: To compare the serum levels of adiponectin and resistin between patients with polycystic ovary syndrome (PCOS)
and healthy control subjects matched for age and body mass index (BMI), and to assess possible correlations of
adiponectin and resistin to the hormonal and metabolic parameters of the syndrome.
Materials and methods: Fifty five patients with PCOS diagnosis composed of 25 obese, 13 overweight, 17 normal weight
subjects, and 49 healthy women matched for age and BMI were included in this study. Hormone and lipid profile,
adiponectin, and resistin were measured in all cases.
Results: Serum adiponectin levels were similar in the lean PCOS patients and the healthy control group. In obese patients
and the control groups, serum adiponectin levels were significantly lower than those in the lean control group. Serum
adiponectin levels were similar in the obese PCOS and the obese control groups. Serum resistin levels were similar in both
patient and control groups. There was a correlation between serum adiponectin levels and fasting insulin, HOMA-IR,
triglyceride, and HDL-C in the PCOS group. A significant correlation in the positive direction was observed among
serum resistin levels and BMI in the patient group.
Conclusion: Our study showed that serum adiponectin levels were lower in obese women with PCOS than in the normal
weight control group. There was a negative correlation between serum adiponectin levels with insulin resistance. We
suggest that resistin is not associated with PCOS pathogenesis but it may be an adipocytokine that is affected by BMI.
Key words: Adiponectin, resistin, PCOS, insulin resistance

Polikistik over sendromu saptanan kadınlarda plazma adiponektin ve rezistin
düzeyleri: vücut kitle indeksi ve insülin direnci ile ilişkisi
Amaç: Serum adiponektin ve rezistin düzeylerinin Polikistik Over Sendromu (PKOS) lu hastalar ile yaş ve vücut kitle
indeksi (VKİ) eşleştirilmiş sağlıklı kontroller arasında karşılaştırılması, adiponektin ve rezistinin, sendromun hormonal
ve metabolik parametreleri ile olası ilişkilerinin değerlendirilmesi amaçlanmıştır.
Yöntem ve gereç: Çalışmaya 25 obez, 13 fazla kilolu, 17 normal kilolu olmak üzere 55 PKOS tanısı almış hasta ile yaş ve
VKİ eşleştirilmiş 49 sağlıklı kadın dahil edildi. Bütün hastalarda adiponektin, rezistin serum düzeyleri ile hormon ve
lipid profili ölçümleri yapıldı.
Bulgular: Normal kilolu PKOS’lu hasta ve kontrol grubu arasında serum adiponektin düzeyleri açısından istatistiksel
anlamda fark saptanmadı (P > 0,05). Obez hastalarda ve obez kontrol grubunda serum adiponektin düzeyleri, normal
kilolu kontrol grubuna göre istatistiksel olarak anlamlı derecede düşük saptandı. Obez PKOS ve obez kontrol grubunun
adiponektin düzeyleri ise benzerdi. Gruplar arasında serum rezistin düzeyleri açısından istatistiksel anlamda farklılık
saptanmadı (P > 0,05). PKOS’lu grupta serum adiponektin düzeyleri ile açlık insülin, HOMA-IR, trigliserid ve HDL-K
arasında bir ilişki saptandı. Hasta grubunda serum rezistin düzeyleri ile VKİ arasında pozitif yönde anlamlı ilişki tespit
edildi.
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Sonuç: Çalışmada, obez PKOS’ lu kadınlarda serum adiponektin düzeyinin normal kilolu kontrol grubuna göre azaldığı
gösterilmiştir. Serum adiponectin düzeyi ile insülin direnci arasında negatif bir ilişki mevcuttur. Rezistinin PKOS
patogenezi ile ilişkili olmadığı ancak VKİ’ den etkilenen bir adipokin olabileceği düşünülmüştür.
Anahtar sözcükler: Adiponektin, resistin, PKOS, insülin direnci

Introduction
Polycystic ovary syndrome (PCOS) is the most
common reproductive disorder, affecting 5%-10% of
women of reproductive age. About 50% of the women
diagnosed with PCOS are overweight. The syndrome
is also associated with multiple cardiovascular risk
factors such as insulin resistance, dyslipidemia, and
hypertension (1,2). However, the mechanism linking
PCOS to the metabolic abnormalities are not
completely understood.
The adipose tissue not only stores a large quantity
of fat as an energy source but also synthesizes several
adipocytokines including adiponectin and resistin.
Adiponectin is a protein hormone produced
exclusively in adipose tissue whose circulating levels
are positively correlated with measures of insulin
sensitivity (3,4). Resistin is also a peptide secreted
from adipose tissue that is assumed to contribute to
peripheral insulin sensitivity. Considering the
frequent clustering of obesity and insulin resistance
in PCOS patients, adiponectin and resistin have been
proposed to play a role in pathogenesis of PCOS (5).
The aim of the present study was to evaluate the
relationships between metabolic alterations and
adiponectin and resistin levels in normal weight, overweight, and obese women with PCOS compared with
age and weight matched healthy women.
Materials and methods
The study group consisted of 55 women with
PCOS (17 normal weight, BMI: 18.5-24.9 kg/m2, 13
overweight, BMI: 25-29.9 kg/m2 and 25 obese, BMI ≥
30 kg/m2) and 49 healthy, normal menstruating
women (17 normal weight, 12 overweight and 20
obese; the control group). The Local Research Ethic
Committee approved the study (2008/49-İAEK:
7110), and all patients involved gave their informed
consent. The study groups were composed of patients
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between 17 and 40 years of age admitted to the
endocrinology outpatient polyclinic with complaints
of irregular menstrual cycles and/or increased hair
growth. The diagnosis of PCOS was established
according to 2003 Rotterdam ESHR/ASRM endocrine
criteria (oligoovulation and/or anovulation, clinical
and/or biochemical hyperandrogenism and polycystic
ovaries as defined by ultrasonography). PCOS can be
diagnosed after the exclusion of other medical
conditions and if she fulfilled 2 out of 3 criteria
mentioned above. Patients with systemic diseases
(diabetes mellitus, thyroid diseases, hypertension,
cardiovascular diseases, chronic renal failure, and
malignancy) and history of taking any other
medication such as lipid lowering, oral contraceptives
pills, ovulation induction, anti-obesity drugs,
corticosteroids, anti-diabetic and antihypertensive
drugs within 6 months were excluded. Before the
study, a physical examination and appropriate
laboratory tests were performed. After overnight
fasting, 75 g oral glucose tolerance test was performed
for all patients and 120 min values obtained. All
patients with diabetes (glucose in 120 min of 75 g
OGTT ≥ 200 mg/dL) were excluded from study. The
diseases that mimic PCOS such as late onset
congenital adrenal hyperplasia and Cushing
syndrome were ruled out by testing 17hydroxyprogesterone and 1 mg dexamethasone
suppression screening test. All patients had normal
thyroid function tests and normal prolactin levels.
The control group was composed of healthy
female volunteers who had regular menstrual cycles
and no signs of clinical and biochemical
hyperandrogenism. The PCOS and the control group
were matched for BMI and age. The body mass index
(BMI) was calculated as body weight in kilograms
2
divided by height in meters squared (kg/m ) at first
admission. The waist circumference was measured at
the widest circumference between the waist and
thighs.
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Serum samples were obtained from all women
during the interval from 2nd to the 5th days of their
early follicular phase of menstrual cycle. Levels of
plasma glucose, insulin, total cholesterol (TC), highdensity lipoprotein cholesterol(HDL-C), triglycerides
(TG), low-density lipoprotein cholesterol (LDL-C),
free and total testosterone, LH, FSH, prolactin, free
T4, free T3, TSH, cortisol, dehydroepiandrosteronesulfate (DHEA-SO4), androstenedion, 17-OH
progesterone, estradiol (E2), sex-hormone binding
globulin (SHBG), adiponectin, and resistin were
measured after 8-12 h fasting. Blood samples were
taken from antecubital vein. The parameters except
adiponectin and resistin were measured immediately.
The blood samples were centrifuged at 4000 rpm for
10 min and separated after collection and were stored
at -80 °C until they were analyzed for adiponectin and
resistin.
Laboratory analyses: Adiponectin was measured
by using enzyme-linked immunosorbent assay
(ELISA), AssayMax Human Adiponectin (Acrp30)
ELISA (Catalog EA2500-1 Lot 0201815 AssayPro,
USA) kit. Resistin was measured by using AssayMax
Human Resistin ELISA (Catalog ER 1001 Lot
0257822 AssayPro, USA) kit. Glucose, TC, HDL, TG,
and LDL were analyzed with an Aeroset analyzer
using Abbott Diagnostics, Wiesbaden, Germany kit.
Insulin, free T4, free T3, TSH, cortisol, prolactin, FSH,
LH, DHEA-SO4, E2, total testosterone levels were
measured
by
electrochemiluminescent
immunometric assay test method with a Cobas
analyzer (Roche Diagnostics, Mannheim, Germany).
SHBG levels were measured by chemiluminescent
immunometric assay test method with an Immulite
2000 analyzer (Siemens Medical Solutions
Diagnostics, Los Angeles, USA). Free testosterone,
androstenedione levels were measured by ELISA. 17OH progesterone levels were measured by enzyme
immune assay method with a Dynex-Dsx analyzer.
Insulin resistance (IR) was determined by a
number of different methods including fasting
insulin, the homeostasis model assessment (HOMA),
and quantitative insulin sensitivity check index
(QUICKI). The estimate of insulin resistance by score
was HOMA-IR score, calculated with the formula:
fasting serum insulin (μU) × fasting plasma glucose
(mg/dL)/405. QUICKI is derived by calculating the

inverse sum of logarithmically expressed values of
fasting insulin and glucose. To define the biochemical
hyperandrogenemia free androgen index was
calculated as follows: Free androgen index: (total
testosterone (nmol/L) / SHBG nmol/L) × 100.
Ultrasonography: The transvaginal and/or
transabdominal ultrasonography were performed in
all patients. The morphology of polycystic ovaries was
considered if there were 12 or more follicles of 2-9
mm in diameter in each ovary and/or enlarged ovary
(>10 cm3).
Statistical analysis: The Statistical Package for the
Social Sciences (SPSS version 13.0 for Windows, SPSS
Inc., Chicago, IL, USA) was used for statistical
analysis. The person doing the data analysis was
blinded to the diagnosis. Results were expressed as
mean ± S.D. The characteristics of distribution were
tested with the Kolmogorov-Smirnov test. Because of
the skewed distribution of insulin, testosterone, and
adiponectin levels, we used log-transformed values in
the subsequent statistical analysis. The clinical and
laboratory characteristics in the 2 groups were
compared by Student’s t-test for unpaired data in the
normal distributed group. The undistributed group
was compared by Mann-Whitney U test. For all
analysis, a P-value less than 0.05 was considered
statistically significant. Bivariate correlation analysis
(calculation of the Pearson coefficient) was used to
assess the correlation of serum adiponectin level to
each parameter.
Results
The patients and controls were separated into 3
groups according to their BMI: normal weight (BMI:
18.5-24.9 kg/m2), overweight (BMI: 25-29.99 kg/m2),
and obese (BMI ≥ 30 kg/m2). The study group
consisted of 55 women with PCOS (17 lean, 13
overweight and 25 obese) and 49 healthy normally
menstruating women (17 lean, 12 overweight and 20
obese; the control group). The clinical characteristics
of the PCOS sub-groups and control groups are
shown in Table 1. In the study, insulin resistance was
found 36% of all patients. We observed a significant
effect of obesity on insulin resistance. Insulin
resistance observed 68% of obese PCOS patients, 15%
of overweight PCOS patients and only 5% of lean
47
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Table 1. Clinical characteristics of the study groups.
Lean PKOS
(n = 17)

Lean control
(n = 17)

Overweight
PCOS (n = 13)

Overweight
control (n = 12)

Obese PCOS
(n = 25)

Obese control
(n = 20)

Age (year)

21.11 ± 2.59

22.70 ± 2.25

22.07 ± 5.18

22.58 ± 2.39

23.72 ± 6.15

23.75 ± 4.5

BMI (kg/m2)

22.36 ± 2.88

20.64 ± 2.12

27.38 ± 1.41

27.02 ± 1.09

34.56 ± 5.72

37.12 ± 5.33

Waist circumference (cm)

80.47 ± 7.45 *

74.29 ± 7.86

89.92 ± 5.37

92.91 ± 8.11

107.72 ± 12.08

111.95 ± 11.85

Hip circumference (cm)

92.94 ± 6.85*

93.47 ± 5.66

103.38 ± 4.83

105.08 ± 3.70

115.88 ± 11.17

122.35 ± 10.15

Waist to hip ratio
Fasting glucose (mg/dL)
Fasting Insulin (μIU/mL)

0.86 ± 0.05

0.79 ± 0.07

0.86 ± 0.03

0.88 ± 0.07

0.92 ± 0.06

0.91 ± 0.06

90.35 ± 8.72 *

82.94 ± 7.65

91.53 ± 6.56

88.25 ± 6.86

92.16 ± 10.86

90.7 ± 5.37
14.37 ± 6.4

6.46 ± 2.94

4.8 ± 1.73

8.91 ± 3.57

8.52 ± 4.67

13.89 ± 6.11

Glucose/Insulin

18.03 ± 10.36

19.89 ± 8.34

12.28 ± 5.69

12.66 ± 5.21

8.99 ± 8.38

7.8 ± 3.82

HOMA-IR

1.44 ± 0.66 *

0.98 ± 0.38

1.98 ± 0.73

1.85 ± 1.01

3.21 ± 1.66

3.22 ± 1.47

QUICKI

0.367 ± 0.036

0.387 ± 0.031

0.346 ± 0.023

0.351 ± 0.025

0.325 ± 0.03

0.324 ± 0.02

Total cholesterol (mg/dL)

167.64 ± 24.09

154.52 ± 33.97

166.23 ± 27.15

179.91 ± 18.37

175 ± 35.34

164 ± 25.25

LDL-C (mg/dL)

90.18 ± 29.48

79.32 ± 24.50

97.43 ± 23.45

110.28 ± 17.34

101.55 ± 30.16

98.16 ± 23.4

HDL-C (mg/dL)

60.35 ± 14.76

61.35 ± 14.39

47.84 ± 11.53

49.66 ± 7.46

50.68 ± 12.54

47.2 ± 7.93

Triglyceride (mg/dL)

85.7 ± 48.60

69.23 ± 22.82

104.76 ± 49.07

84.83 ± 27.03

115.75 ± 66.35

97.2 ± 49.22
4.73 ± 1.88

LH (mIU/mL)

11.92 ± 7.05 *

4.55 ± 2.71

16.15 ± 13.06 #

5.63 ± 1.60

9.44 ± 5.77 ¶

FSH (mIU/mL)

5.19 ± 1.84

5.44 ± 2.13

6.02 ± 1.87

5.74 ± 2.29

5.56 ± 1.46

5.51 ± 1.79

LH/FSH

2.4 ± 1.39 *

0.87 ± 0.57

2.77 ± 2.1#

1.20 ± 0.74

1.72 ± 1.09 ¶

0.92 ± 0.46

DHEA-SO4 (μg/dL)

281.23 ± 89.50 *

179.10 ± 79.45

267.69 ± 122.21

203.81 ± 93.40

302.8 ± 109.34¶

165.43 ± 69.89

Total testosterone (ng/dL)

73.57 ± 28.64 *

33.53 ± 13.29

84.33 ± 47.87 #

38.21 ± 16.09

74.51 ± 24.04 ¶

33.13 ± 15.81

SHBG (nmol/L)

33.75 ± 10.98*

64.73 ± 39.90

23.61 ± 11.92 #

39.32 ± 11.66

20.99 ± 12.02 ¶

29.31 ± 10.21

Free androgen index

8.84 ± 4.71 *

2.78 ± 2.47

17.66 ± 21.30 #

3.76 ± 2.12

16.96 ± 10.32 ¶

4.27 ± 2.20

Free testosterone (pg/mL)

4.85 ± 3.45 *

2.61 ± 1.66

4.93 ± 4.87 #

1.94 ± 1.54

4.85 ± 3.10 ¶

2.46 ± 1.60

Androstenedion (ng/mL)

6.31 ± 4.92 *

2.39 ± 0.88

5.13 ± 4.53

2.72 ± 1.20

4.94 ± 2.90 ¶

2.33 ± 0.85

17-OH Progesterone (ng/mL)

0.94 ± 0.45 *

0.61 ± 0.40

0.80 ± 0.43

0.50 ± 0.23

0.84 ± 0.39¶

0.60 ± 0.38

Adiponectin (ng/mL)

30.9 ± 18.3

37.82 ± 20.2

24.7 ± 12.7

31.66 ± 11.9

23.5 ± 11.7

25.8 ± 14.4

Resistin (ng/mL)

1.27 ± 0.53

1.66 ± 0.99

1.33 ± 0.29

1.59 ± 0.55

1.44 ± 0.40

1.44 ± 0.49

Data are presented as mean ± SD,* P < 0.05 for difference between respective lean PCOS and the lean control groups, #P < 0.05 for difference between
respective overweight PCOS and the overweight control groups, ¶ P < 0.05 for difference between respective obese PCOS and the obese control groups.

PCOS patients. Impaired glucose tolerance was
determined in 20% of patients with PCOS. Fasting
glucose levels seemed to be higher in the lean PCOS
patients than in lean control women and reached
statistical significance (P = 0.013). Fasting insulin
levels was higher in the PCOS group than in the
control group but did not reach statistical significance
(P = 0.055). HOMA-IR was significantly higher in the
normal weight PCOS group (HOMA-IR: 1.44 ± 0.66)
than in the control group (HOMA-IR: 0.98 ± 0.38)
and reached statistical significance (P = 0.021). The
levels of LH, DHEA-SO4, total and free testosterone,
free androgen index, androstenedion, and 17-OH
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progesterone were significantly higher in the lean
PCOS group than in the lean controls. SHBG levels
were significantly lower. However, there were no
statistically significant differences in serum TC, HDLC, TG, LDL-C, LH, FSH, prolactin, free T4, free T3,
TSH, cortisol, or estradiol levels between the lean
PCOS group and the control group (P > 0.05).
In overweight PCOS patients serum LH, total
testosterone, free testosterone, and free androgen
index were significantly higher than they were in the
overweight control group. Serum LH, DHEA-SO4,
free androgen index, total and free testosterone, 17OH progesterone and androstenedione levels were
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higher in the obese PCOS group than in the obese
controls. SHBG level in the control group was higher
than that in the PCOS group and the difference was
statistically significant.
There were no statistically significant differences
in serum adiponectin concentrations of the lean
PCOS and control groups (P > 0.05). Serum
adiponectin concentrations of the obese PCOS group
were lower than those of the lean PCOS group and the
lean control group and the difference was statistically
significant. There was no difference in serum
adiponectin concentrations of obese PCOS and the
obese control group. There were no statistically
significant differences in serum resistin
concentrations between the groups (P > 0.05).
Relationships of serum adiponectin and resistin with
anthropometric, biochemical, and hormonal
parameters are shown in Table 2. Fasting adiponectin
levels showed a significant correlation with insulin
resistance indices in the PCOS group. Adiponectin
was negatively correlated with insulin and HOMA–
IR (P = 0.008, P = 0.012). Adiponectin showed a
positive correlation with QUİCKİ. (P = 0.013). Also
serum adiponectin showed a positive correlation with
Table 2. Relationships of serum adiponectin and resistin with
anthropometric, biochemical, and hormonal parameters
in patients with PCOS.
Adiponectin

Resistin

r

P

r

P

0.003

0.981

0.163

0.235

BMI (kg/m )

-0.227

0.095

0.284

0.036

Waist circumference

-0.173

0.205

0.298

0.027

Insulin (μU/mL)

-0.353

0.008

0.185

0.177

HOMA-IR

-0.338

0.012

0.218

0.110

QUICKI

0.334

0.013

-0.237

0.082

Total cholesterol (mg/dL)

-0.130

0.344

0.029

0.836

LDL-C (mg/dL)

-0.208

0.127

0.185

0.177

HDL-C (mg/dL)

0.399

0.003

-0.453

0.001

Triglyceride (mg/dL)

-0.276

0.041

0.216

0.113

LH (mIU/mL)

0.003

0.981

-0.020

0.885

FSH (mIU/mL)

-0.089

0.520

-0.104

0.449

Total testosterone (ng/dL)

-0.172

0.210

-0.133

0.333

SHBG (nmol/L)

0.308

0.022

-0.234

0.086

Free androgen index

-0.268

0.048

0.096

0.486

Age (years)
2

HDL (P = 0.003) and a negative correlation with
triglycerides (TG). SHBG and adiponectin showed a
positive correlation (P = 0.022) while free androgen
index and adiponectin showed a negative one (P =
0.048). There was a positive correlation between the
BMI and resistin levels (P = 0.036). A positive
correlation was found between resistin and waist
circumference (P = 0.027). A strong negative linear
correlation was observed between resistin and HDLC levels (P = 0.001).
Discussion
Polycystic ovary syndrome (PCOS) is a common
endocrine disorder frequently associated with insulin
resistance and obesity leading to long-term health
risks including type 2 DM, dyslipidemia, and
cardiovascular diseases, and manifesting with signs
and symptoms of chronic anovulation and
hyperandrogenism in reproductive females.
Insulin resistance, which plays a significant role
in the pathophysiology of PCOS, is encountered as an
important parameter determined in nearly 50% of the
patients (6). It is known that the relationship is
strengthened in the presence of obesity. HOMA-IR
values were significantly higher in PCOS patients with
normal weight in comparison to the control group
with normal weight, but a similar relation could not
be demonstrated between obese and overweight
patients and the control group. Higher HOMA-IR
level, one of insulin resistance indices, in patients with
normal weight in comparison to the age- and BMImatched control group, is considered an important
result supported by literature where insulin resistance
in PCOS occurs independently of obesity (7). The best
method for determining glucose homeostasis
anomalies in PCOS is an oral glucose test (8). The
main risk factors responsible for occurrence of
glucose intolerance in PCOS are age, BMI, body fat
distribution, and familial diabetes history. Impaired
glucose tolerance and diabetes occurrence rates were
increased particularly in obese patients.
Following the discovery of the hormone leptin in
1994, it is clarified that fatty tissue not only regulates
the energy metabolism of our body, it also releases
many biological molecules cumulatively referred as
adipo(cyto)kines, which contribute to peripheral
49
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insulin sensitivity. In addition, in PCOS, which is
regarded among the important features of insulin
resistance and central obesity, the role of adipokines in
the pathogenesis of the syndrome has attracted
attention. Adiponectin is possibly the most important
adipocytokine of the fatty tissue. The reason is that it
is cytokine only that is synthesized at and released
from fatty tissue, and it has well established antiatherogenic, anti-inflammatory, and insulin sensitizer
properties. It is known that adiponectin levels
significantly decreases in obese subjects relative to
subjects with normal weight (9). Moreover, it was
found that serum adiponectin concentrations are
inversely related with severity of insulin resistance
(10). Taking into consideration the relation of PCOS
with obesity and insulin resistance, the role of
adiponectin in the pathogenesis of PCOS and whether
or not there is a relation with insulin resistance in
PCOS attracted our attention.
Studies about the adiponectin levels in PCOS
patients have controversial results. PCOS women
generally show hypoadiponectinemia. Authors
suggested that obesity, insulin resistance, or
hyperandrogenemia may be the cause of
hypoadiponectinemia in women with PCOS. In the
study, no difference was found in serum adiponectin
levels between the PCOS patients with normal weight
and the control group with normal weight, but serum
adiponectin levels in obese patients were significantly
lower than those in PCOS patients and the control
group, both with normal weight. Adiponectin levels
were similar in the obese PCOS and obese control
groups. In several previous studies, serum
adiponectin levels were found to be similar in the
patients with PCOS and BMI-matched control group,
which further supported the results of our study (1114). Similar to our study, some of above-mentioned
studies found that serum adiponectin levels of obese
and overweight patients with PCOS were significantly
lower than those in the PCOS patients with normal
weight (11-13). Lack of a significant difference in
serum adiponectin levels between PCOS patients and
the control group with similar BMI leads to the
suggestion that adiponectin has no direct role in the
pathogenesis of PCOS (11-14). In contrast, some
other studies demonstrated that serum adiponectin
levels of patients with PCOS were significantly lower
50

than those in BMI-matched controls, a finding
suggestive of the role played by adiponectin in the
pathogenesis of the syndrome (15-19).
In our study, it was determined that serum
adiponectin levels had negative correlations with
fasting insulin level and HOMA-IR, but serum levels
had positive relations with QUICKI. This finding is
of importance to indicate that serum adiponectin
levels are inversely correlated depending on the
severity of insulin resistance and the finding is
compatible with the literature (10). This relation
indicates that obesity is not only a factor in the
development of insulin resistance in PCOS patients
and that adiponectin may be another factor
contributing to insulin resistance. Nevertheless, the
relation between insulin resistance in PCOS and
adiponectin is still controversial. While some
investigators suggest that changes in adiponectin
concentrations in the patients with PCOS are related
to changes in the quantity of fatty tissue (11,12),
others advocate the view that adiponectin is related to
insulin resistance independent of obesity (13,14). In
some studies, a negative correlation between serum
adiponectin levels in PCOS patients and BMI was
emphasized but a similar relation was not found in
our study (11-14,19).
In our study, a positive correlation between serum
adiponectin levels of patients with PCOS and SHBG
and a negative correlation with free androgen index
were found. A study conducted by Panidis et al.
provided a result similar to that of our study, but in
their study the fact that SHBG and androgen index
were not independent factors influencing adiponectin
levels was considered to have a possible relation with
obesity (12). In the study conducted by EscobarMorreale et al., it was suggested that
hypoadiponectinemia in patients with PCOS may be
a consequence of hyperandrogenism associated with
abdominal obesity (18). There are also studies
indicating that androgens reduce serum adiponectin
levels (20). There are studies suggesting that
adiponectin levels are negatively correlated with
triglyceride level and positively correlated with HDLcholesterol (21). In our study, a similar finding
consistent with the literature was obtained.
Resistin is an adipokine suggested to be released
in large amounts from macrophages besides the fatty
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tissue of humans. Moreover, the relation of resistin
with obesity and insulin resistance has yet to be
clarified. This molecule is regarded as a hormone
leading to insulin resistance as it was demonstrated
that while serum resistin level increase in the presence
of obesity in mice an anti-diabetic agent rosiglitazone
decreased levels and that administration of
recombinant resistin to mice caused impairment in
glucose tolerance and insulin effect. Therefore,
Steppan et al. named this new hormone
(resist+in[sulin]) (22). Although there are studies
supporting the relation between resistin and obesity
and insulin resistance, there are also studies reporting
contrary views (23-26).
As in many other studies (23-26), our study did
not determine a difference between BMI-matched
PCOS patients and control groups in terms of serum
resistin levels. Panidis et al. found a positive
correlation between serum resistin levels and BMI in
patients with PCOS and they also emphasized that
resistin played no role in the pathogenesis of insulin
resistance in PCOS, but it may be related with obesity
(27). In our study, a linear relation was determined in
the group of patients with PCOS between serum

resistin levels and BMI and waist circumference and
the finding was compatible with the literature. Seow et
al. not only found that serum resistin levels in patients
with PCOS were similar to those of the control group,
but they also determined that resistin mRNA
expression in adiposities was 2-fold higher in the
group of patients with PCOS than the control group.
In the light of this finding, they suggested that resistin
might cause a local paracrine effect in obesity and
insulin resistance in PCOS (28).
Additionally, a negative correlation between
serum resistin levels and HDL cholesterol was
determined in our study. This finding was regarded
to result from obesity rather than the effect of resistin
on lipid parameters.
In conclusion, our data showed that adiponectin
levels were decreased in obese PCOS patients. The
study also supports a negative correlation between
adiponectin and insulin resistance. We suggest that
resistin is not associated with PCOS pathogenesis but
it may be an adipocytokine that is affected by BMI.
Detailed retrospective studies with long term followup and larger populations are required with respect
to the clinical significance of these findings.
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